- Home
- LYRA vs APM Comparison
LYRA vs APM Comparison
Compare LYRA & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- APM
- Stock Information
- Founded
- LYRA 2005
- APM 2010
- Country
- LYRA United States
- APM United Kingdom
- Employees
- LYRA N/A
- APM N/A
- Industry
- LYRA Medical/Dental Instruments
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- APM Health Care
- Exchange
- LYRA Nasdaq
- APM Nasdaq
- Market Cap
- LYRA 6.1M
- APM 5.6M
- IPO Year
- LYRA 2020
- APM 2018
- Fundamental
- Price
- LYRA $0.10
- APM $0.99
- Analyst Decision
- LYRA Hold
- APM
- Analyst Count
- LYRA 4
- APM 0
- Target Price
- LYRA $1.25
- APM N/A
- AVG Volume (30 Days)
- LYRA 1.7M
- APM 138.3K
- Earning Date
- LYRA 04-29-2025
- APM 05-06-2025
- Dividend Yield
- LYRA N/A
- APM N/A
- EPS Growth
- LYRA N/A
- APM N/A
- EPS
- LYRA N/A
- APM 0.00
- Revenue
- LYRA $1,534,000.00
- APM N/A
- Revenue This Year
- LYRA N/A
- APM $157,729.10
- Revenue Next Year
- LYRA $237.15
- APM N/A
- P/E Ratio
- LYRA N/A
- APM $270.99
- Revenue Growth
- LYRA N/A
- APM N/A
- 52 Week Low
- LYRA $0.08
- APM $0.46
- 52 Week High
- LYRA $5.65
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- LYRA 38.11
- APM 51.54
- Support Level
- LYRA $0.08
- APM $0.79
- Resistance Level
- LYRA $0.10
- APM $0.97
- Average True Range (ATR)
- LYRA 0.02
- APM 0.12
- MACD
- LYRA 0.00
- APM 0.02
- Stochastic Oscillator
- LYRA 41.71
- APM 33.74
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.